These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

737 related articles for article (PubMed ID: 26233732)

  • 21. Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease.
    Peng YL; Tain YL; Lee CT; Yang YH; Huang YB; Wen YH; Hsu CN
    Sci Rep; 2020 Jul; 10(1):10734. PubMed ID: 32612180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Febuxostat on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension: A Phase 2 Randomized Placebo-Controlled Study.
    Gunawardhana L; McLean L; Punzi HA; Hunt B; Palmer RN; Whelton A; Feig DI
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29102979
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Febuxostat on Renal Function in Gout Patients With Moderate-to-Severe Renal Impairment.
    Saag KG; Whelton A; Becker MA; MacDonald P; Hunt B; Gunawardhana L
    Arthritis Rheumatol; 2016 Aug; 68(8):2035-43. PubMed ID: 26894653
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Study of therapeutic efficacy of febuxostat in chronic kidney disease stage IIIA to stage VD.
    Sarvepalli PS; Fatima M; Quadri AK; Taher AR; Habeeb A; Amreen F; Parveen BN; Rajaram KG
    Saudi J Kidney Dis Transpl; 2018; 29(5):1050-1056. PubMed ID: 30381500
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of febuxostat in patients with allopurinol-refractory hyperuricemic chronic kidney disease
.
    Kwak CH; Sohn M; Han N; Cho YS; Kim YS; Oh JM
    Int J Clin Pharmacol Ther; 2018 Jul; 56(7):321-327. PubMed ID: 29750634
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review.
    Hu AM; Brown JN
    Clin Rheumatol; 2020 Nov; 39(11):3287-3294. PubMed ID: 32418037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent evidence on the effect of urate-lowering treatment on the progression of kidney disease.
    Tiku A; Johnson DW; Badve SV
    Curr Opin Nephrol Hypertens; 2021 May; 30(3):346-352. PubMed ID: 33767063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial.
    Tanaka K; Nakayama M; Kanno M; Kimura H; Watanabe K; Tani Y; Hayashi Y; Asahi K; Terawaki H; Watanabe T
    Clin Exp Nephrol; 2015 Dec; 19(6):1044-53. PubMed ID: 25676011
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Febuxostat is superior to allopurinol in delaying the progression of renal impairment in patients with chronic kidney disease and hyperuricemia.
    Zhang X; Wan D; Yang G; Peng Q; Wang X
    Int Urol Nephrol; 2019 Dec; 51(12):2273-2283. PubMed ID: 31646459
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and Efficacy of Benzbromarone and Febuxostat in Hyperuricemia Patients with Chronic Kidney Disease: A Prospective Pilot Study.
    Yu H; Liu X; Song Y; Cheng J; Bao H; Qin L; Zhou X; Wang L; Peng A
    Clin Exp Nephrol; 2018 Dec; 22(6):1324-1330. PubMed ID: 29761242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
    Yang N; Cao B
    J Clin Pharm Ther; 2022 Dec; 47(12):2214-2222. PubMed ID: 36403976
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Febuxostat, a Xanthine Oxidase Inhibitor, on Cardiovascular Risk in Hyperuricemic Patients with Hypertension: A Prospective, Open-label, Pilot Study.
    Tani S; Nagao K; Hirayama A
    Clin Drug Investig; 2015 Dec; 35(12):823-31. PubMed ID: 26482071
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention of kidney function decline using uric acid-lowering therapy in chronic kidney disease patients: a systematic review and network meta-analysis.
    Tsukamoto S; Okami N; Yamada T; Azushima K; Yamaji T; Kinguchi S; Uneda K; Kanaoka T; Wakui H; Tamura K
    Clin Rheumatol; 2022 Mar; 41(3):911-919. PubMed ID: 34642880
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Urate-lowering therapy for CKD patients with asymptomatic hyperuricemia without proteinuria elucidated by attribute-based research in the FEATHER Study.
    Kataoka H; Mochizuki T; Ohara M; Tsuruta Y; Iwasa N; Yoshida R; Tsuchiya K; Nitta K; Kimura K; Hosoya T;
    Sci Rep; 2022 Mar; 12(1):3784. PubMed ID: 35260678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Superior effect of allopurinol compared to febuxostat on the retardation of chronic kidney disease progression.
    Park S; Lee JP; Kim DK; Kim YS; Lim CS
    PLoS One; 2022; 17(2):e0264627. PubMed ID: 35226683
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Febuxostat as a renoprotective agent for treatment of hyperuricaemia: a meta-analysis of randomised controlled trials.
    Chewcharat A; Chen Y; Thongprayoon C; Harrison AM; Mao MA; Cheungpasitporn W
    Intern Med J; 2021 May; 51(5):752-762. PubMed ID: 32149437
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study.
    Gunawardhana L; Becker MA; Whelton A; Hunt B; Castillo M; Saag K
    Arthritis Res Ther; 2018 May; 20(1):99. PubMed ID: 29848361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
    Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
    Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of Febuxostat on Oxidative Stress.
    Fukui T; Maruyama M; Yamauchi K; Yoshitaka S; Yasuda T; Abe Y
    Clin Ther; 2015 Jul; 37(7):1396-401. PubMed ID: 25913922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of Uric Acid Levels on Kidney Disease Progression.
    Rincon-Choles H; Jolly SE; Arrigain S; Konig V; Schold JD; Nakhoul G; Navaneethan SD; Nally JV; Rothberg MB
    Am J Nephrol; 2017; 46(4):315-322. PubMed ID: 29032376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.